O. Ivakhnenko

ORCID: 0000-0002-9483-3171
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis C virus research
  • Healthcare Systems and Public Health
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical studies and practices
  • Pharmaceutical Economics and Policy
  • Economic, Social, and Public Health Issues in Russia and Globally
  • Rheumatoid Arthritis Research and Therapies
  • Liver Disease Diagnosis and Treatment
  • Acute Ischemic Stroke Management
  • Neurological Disorders and Treatments
  • Pneumonia and Respiratory Infections
  • Schizophrenia research and treatment
  • Spondyloarthritis Studies and Treatments
  • Hepatitis B Virus Studies
  • Pulmonary Hypertension Research and Treatments
  • Diet and metabolism studies
  • Multiple and Secondary Primary Cancers
  • Psoriasis: Treatment and Pathogenesis
  • Biosimilars and Bioanalytical Methods
  • Multiple Myeloma Research and Treatments
  • Adolescent and Pediatric Healthcare
  • Retinal and Optic Conditions
  • Urinary Tract Infections Management
  • Pain Management and Placebo Effect
  • Lung Cancer Research Studies

Sechenov University
2021-2024

Center for Assessment
2022

Financial Research Institute of the Ministry of Finance of the Russian Federation
2017-2020

Federal State Budgetary Institution "Center for Expertise and Quality Control of Medical Care"
2020

Ministry of Health of the Russian Federation
2018-2019

The accessibility and pharmaceutical care coverage are linked to political, economic managerial decisions. That fact necessitates the evaluation of state programs results in field drug provision. aim work was assess quantitative implementation High-Cost Nosologies program Russian Federation from 2008 2023 determine further vectors its improvement. Materials methods. regulatory base made up legislation open sources were used as research information for data collection analysis: reports...

10.19163/2307-9266-2024-12-1-15-31 article EN cc-by Pharmacy & Pharmacology 2024-05-07

Diabetic retinopathy (DR) and age-related macular degeneration (AMD) comprise a significant socio-medical problem for Russia. The article presents an analysis aimed at identifying the prerequisites further research on socio-economic consequences of retinal pathology. Studying epidemiological aspects DR AMD, as well conditions receiving medical aid helped define main approaches to assessing economic burden diseases in It also revealed problems associated with completeness registration...

10.17116/oftalma2021137011123 article EN Russian Annals of Ophthalmology 2021-01-01

The article presents a description of amendments the Russian Federation Government Decree No. 871 from August 28, 2014 (with November 20, 2018). authors analyzed historical development approaches for complex drug assessment in Russia, also criteria its evaluation were under investigation. changes affecting both order and procedure forming lists medical drugs use are reviewed. particularities current formation described detail. In reliance on analysis, further direction...

10.17749/2070-4909/farmakoekonomika.2020.032 article EN cc-by-nc-sa FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology 2020-08-09

Журнал для непрерывного медицинского образования врачей Результаты прогнозирования эпидемической ситуации по гепатиту С в зависимости от стратегии

10.33029/2305-3496-2020-9-4-60-71 article RU Infectious diseases News Opinions Training 2020-01-01

Objective: to assess clinical and economic implications of adding daratumumab (Dara) the “lenalidomide + dexamethasone” (Rd) treatment program in early lines therapy for patients with multiple myeloma (MM) ineligible high-dose chemotherapy (HDCT) subsequent autologous hematopoietic stem cell transplantation (autoHPSCT). Material methods . Partitioned survival model was developed compare overall programs MM 1st 3rd therapy. The following options were included analysis: line – Dara+Rd; 2nd...

10.17749/2070-4909/farmakoekonomika.2024.237 article EN cc-by-nc-sa FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology 2024-05-03

Results of the assessment methodological quality economic evaluations (EE), submitted to justify inclusion/exclusion drugs in lists for medical use (list vital and essential drugs, additional medication supply list expensive drug list), are given article. The study was conducted 2018 FSBI “Center healthcare control” Ministry Health Russian Federation. Assessment performed based on 12 criteria accordance with requirements evaluations, described draft Order Government Federation, No. 871, then...

10.31556/2219-0678.2019.35.1.008-017 article EN Medical Technologies Assessment and Choice 2019-05-01

Introduction. The state guarantee program for provision of free medical care to citizens is a key regulatory document that describes the actual guarantees care. standards extent and financing established in it, determine level throughout Russian Federation. aim possible limitations within formation indicators provided regions Federation corresponding financial support. Materials methods . As part study, federal regional legal acts were analyzed, terms methodology programs guarantees,...

10.17749/2070-4909.2019.12.3.221-229 article EN cc-by-nc-sa FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology 2019-10-28

Aim. Impact evaluation of effective methods for advanced small cell lung cancer treatment using the drug durvalumab on achievement Russian Federation national and regional programs Healthcare Development target indicator reduction mortality from neoplasms.
 Materials methods. The methodology this study is based general scientific research methods: logical (analysis, synthesis, induction), theoretical (generalization), empirical (description, calculation, measurement, comparison)....

10.26442/18151434.2022.1.201498 article EN Journal of Modern Oncology 2022-04-30

The article provides the results of assessment methodological quality budget impact analysis (BIA) submitted as a justification for inclusion/exclusion drugs into lists medical use (Vital and Essential Drug list, List Drugs Certain Categories Citizens, High-Cost Drugs) in 2018.The was performed by Center Healthcare Quality Assessment Control Ministry Health Russian Federation according to requirements, described Order Government Federation, № 871 (version from 29.10.2018), which consist 11...

10.31556/2219-0678.2018.34.4.011-018 article EN Medical Technologies Assessment and Choice 2018-12-01

<p style="text-align: justify;"><span style="color: #993300;"><span style="line-height: 1.538em;"><span #993300;">https://doi.org/10.31288/oftalmolzh201462934</span></span></span> #993300;"><strong><span 1.538em;">Hemodynamic effect of indirect revascularization interventions in the treatment rhegmatogenous retinal detachment</span></strong></span> justify;"><strong>N. G. Zavhorodnya 1 2, A. V. Dedov 1, 0. M. Ivakhnenko</strong>

10.31288/oftalmolzh201462934 article EN Oftalmologicheskii Zhurnal 2014-12-09

To assess the cost-effectiveness of retreatment with pegylated interferon and ribavirin in combination boceprevir HCV genotype 1 patients, who failed to respond previous treatment, comparison absence ribavirin. We performed analysis. Based on published data we modeled number long-term unfavorable outcomes (liver cirrhosis, hepatocellular carcinoma death) hypothetic cohort patients following one three strategies: “no treatment” (NT), “peginterferon+ribavirin” (PR) “peginterferon + boceprevir”...

10.1016/j.jval.2013.08.1120 article EN publisher-specific-oa Value in Health 2013-10-22

10.1016/s1098-3015(11)72818-2 article EN publisher-specific-oa Value in Health 2010-11-01
Coming Soon ...